Contact
Asma advises French and international clients within our Intellectual Property department with respect to the drafting and the filing strategy of their patents. She also represents them before the EPO in opposition proceedings.
As an engineer in biotechnology, she mainly focuses her activity on patents in this field as well as in the pharmaceutical industry.
Asma joined our team in 2018. Beforehand, she has been practicing for 5 years in an IP law firm and for 2.5 years in an international law firm wherein she gained experience in patent litigation.
Graduated from the CEIPI, she is also qualified as a French and European patent attorney, and has passed the Patent litigation certificate in 2018.
French | English
AD Article
E-filing of French patent applications: French PTO (INPI) shuffle its feet after messing with PLT
August & Debouzy wins its proceedings for exceeding its power (ultra vires) before the Conseil d'Etat against the decision of the Director of the
AD Article
Preliminary Injunction on the basis of a Patent Application – Another French Oddity?
In an interim order dated 3 June 2022, the President of the Paris Judicial Court: • Ruled that a motion for interim injunction based on Article
AD Article
Opposition before the INPI: publication of the first opposition decision
In our article of 2 March 2022, we reported our impressions on the firsts oral proceedings before the INPI[1] and pointed out that they are very similar to
AD Article
The SPC system: a flawed system in need of reform? That is the question... asked by the European Commission
In view of the imminent launch of the Unified Patent Court (“UPC”) and following the publication, in 2020, of its “Intellectual Property Action Plan”, its “Pharmaceutical Strategy for Europe” and its report on the evaluation of the current Supplementary Protection Certificate (“SPC”) regime, the European Commission launched on 8 March a call for evidence to gather opinions on a possible reform of the SPC system.
AD Article
Patent opposition before the INPI: veni, vidi, now being able to tell how it could be
The opposition proceedings before the INPI came into force on 1st April 2020 and is off to a good start, with around twenty oppositions having been filed, mainly by strawmen but also by foreign companies. The oral proceedings started on 25 January 2022, and we attended and participated in the first four. Here we share our first impressions before the oral proceedings resume in mid-March. On the whole, the course of oral proceedings before the INPI is very similar to that of the European Patent Office (EPO) with, nevertheless, a notable singularity: the INPI seems to be more welcoming of late submissions.
AD Deal
August Debouzy, alongside the founders in the transfer of control of Laboratoires Majorelle to EW Healthcare Partners.
August Debouzy advised the founders in the context of the sale of the Laboratoires Majorelle to EW Healthcare Partners for an undisclosed amount.
AD Article
The Opposition before the French Patent Office
Today is the day of the “launch” of the opposition procedure before the French Patent Office (“Institut National de la Propriété Intellectuelle” or “INPI”). This procedure is a new way to challenge the validity of a French patent, alongside the claim for invalidity.
AD Article
Publication of Decree No. 2020-225 of March 6, 2020 on the opposition procedure for French patents and setting of the opposition fee
The decree n°2020-225, taken for the application of the ordinance n°2020-116 which creates a right of opposition to French patents, was published in the Official Journal on March 6, 2020.
AD Article
Publication of Ordinance No. 2020-116 of 12 February 2020 creating a right of opposition to French patents
On 13 February 2020, Order No. 2020-116 was published in the Official Journal. It creates a right of opposition to the French patents before the INPI. The content of this ordinance is summarized in the report to the President of the Republic published the same day.
More
Publications